PH: S0031-9422(97)00389-0

A GUAIANOLIDE AND A GERMACRANOLIDE FROM *ACHILLEA*SANTOLINA

Basma A. A. A. Balboul,* Ahmed A. Ahmed,† Hideaki Otsuka,‡ Masahiko Bando,§ Masaru Kido§ and Yoshio Takeda¶

Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan; †Department of Chemistry, Faculty of Science, Minia University, El-Minia 61519, Egypt; §Second Tokushima Institute of New Drug Research, Otsuka Pharmaceutical Co. Ltd, Tokushima 771-01, Japan; ¶Faculty of Integrated Arts and Sciences, The University of Tokushima, 1-1 Minamijosanjima-cho, Tokushima 770, Japan

(Received in revised form 14 April 1997)

Key Word Index—*Achillea santolina*; Compositae; Anthemideae; guaianolide; germacranolide; flavonoid; santoflavone; X-ray analysis.

Abstract—An extract of whole plants of Achillea santolina afforded a new guaianolide and a new germacranolide in addition to two known guaianolides and three flavonoids. Structures were elucidated by spectroscopic methods, and the structure of the germacranolide was confirmed by a single crystal X-ray analysis. © 1997 Elsevier Science Ltd

INTRODUCTION

The genus Achillea comprises over 100 species distributed worldwide. Achillea species exhibit pharmacological activities such as anti-bacterial [1], anti-inflammatory [2] and antiallergic [3] properties.

Many species, including A. santolina have been studied, and in addition to taxonomic studies on the distribution of flavonoids [4, 5], attention is still being paid to the sesquiterpene lactones [6–9]. Most species contain guaianolides [10], germacranolides [11], and less frequently eudesmanolides [12].

Phytochemical reinvestigation of A. santolina collected in north Egypt afforded in addition to the known compounds leucodin (1) [13], desacetylmatricarin (2) [13], and three flavonoids (6-8), a new guaianolide and a new germacranolide, 3 and 4, respectively.

RESULTS AND DISCUSSION

The compounds were purified by various types of chromatography (see experimental), and the structures of known compounds, 1, 2, 7 and 8, were elucidated by comparison with reported physical data.

The elemental composition of 3 was C₁₅H₁₈O₄ by HR-FAB-mass spectroscopy. The ¹H NMR data

(Table 1) showed the presence of a derivative of leucodin [13]. From the missing coupling $J_{5,6}$, the position of an additional hydroxyl group was deduced to be at C-5. Its α -orientation was confirmed by the downfield shift of the H-7 and H-9 α signals, compared with those in leucodin (Table 1). The large coupling constant ($J_{6,7} = 10$ Hz) confirmed the *trans*-arrangement of H-6 and 7. Therefore, the structure of 3 was 5-hydroxyleukodin.

^{*}On leave from Faculty of Science, Minia University, Egypt.

[‡] Author to whom correspondence should be addressed.

Table 1, ¹H NMR data of compounds 1 and 3-5 (400 MHz, CDCl₃)

	1	3	4	5*
H-1		_	5.08, ddd, 2/3/12	5.25, br dd, 4/12
Η-2α	_	_	2.55, m	2.58, ddd, 4/5/13
$H-2\beta$	_	_	2.36, dt, 10/12	2.35, ddd, 11/12/13
H-3	6.14, qui, 1	6.11, d, 0.5	5.17, dd, 6/10	5.19, dd, 5/11
H-5	3.48, br d, 10	_	4.42, brd, 10	4.81, brd, 9
H-6	3.60, t, 10	3.86, d, 10	5.41, d, 10	4.58, dd, 9/10
H-7	1.94, dtd, 3/10/13	2.72, dtd, 3/10/13		2.70, dddd, 3/3.5/10/10
Η-8α	1.98, m	2.01, ddd, 3/6/13	3.30, dd, 1/13	2.18, dd, 3/13
Η-8β	1.35, q, 13	1.39, q, 13	2.58, dd, 10/13	1.93, ddd 10/10/13
Η-9α	2.31, ddd, 2/13/13	$2.90, \hat{b}r t, 13$	5.14, dd, 1/10	5.16, dd, 3/10
Η-9β	†	2.17, dd, 6/13	-	
H-11	2.23, dq, 7/13	2.20, qd, 6/13		_
H-13	1.24 (3H), d, 7	1.26 (3H), d, 6	4.46, d, 14	5.58, d, 3
H-13′	_ ` ` ` ` ` `	_	4.51, d, 14	6.25, d, 3.5
H-14	2.41, s	2.39, s	1.67, s	1.50, br s
H-15	2.27, d, 1	2.33, s	1.74, <i>d</i> , 1	1.73, br s
MeCO			2.09, s	2.06, s
			2.10, s	2.11, s

^{*} Data taken from ref. [15].

Table 2. ¹³C NMR data of compounds 1, 3 and 4 (100 MHz, CDCl₁)

	/	
1	3	4
131.8	134.2	127.9
195.8	194.1	30.2
135.4	135.2	77.6
169.9	171.5	137.3
52.5	79.5	122.7
84.1	86.2	80.2
56.3	47.6	159.8
25.9	27.3	32.5
37.5	35.1	79.5
152.1	155.4	135.3
41.1	41.1	131.8
177.5	177.5	172.9
12.2	12.3	54.6
21.5	22.3	11.4
19.7	15.6	11.7
		21.2, 21.0
		170.7, 169.8
	131.8 195.8 135.4 169.9 52.5 84.1 56.3 25.9 37.5 152.1 41.1 177.5 12.2 21.5	131.8 134.2 195.8 194.1 135.4 135.2 169.9 171.5 52.5 79.5 84.1 86.2 56.3 47.6 25.9 27.3 37.5 35.1 152.1 155.4 41.1 41.1 177.5 177.5 12.2 12.3 21.5 22.3

The elemental composition of **4** was $C_{19}H_{24}O_7$ by HR-FAB-mass spectrometry. The ¹H NMR spectral data of 4 (Table 1) showed that it was a sesquiterpene lactone of the *trans*, *trans*-germacranolide type. The ¹H NMR spectrum exhibited a methyl singlet at δ_H 1.67 (H₃-14), a doublet at δ_H 1.74 (H₃-15), and two acetyl singlets at δ_H 2.09 and 2.10. The stereochemistries at C-3 and C-9 were tentatively deduced from the couplings ($J_{9\alpha,8\beta}=10$ Hz, and $J_{2.3}=6$ Hz) [14], and by comparison with haageanolide acetate (**5**) [15]. From the ¹³H NMR and DEPT spectra, a carbon signal with two hydrogen atoms [δ_C 54.9 with δ_H 4.46 and 4.51] could be ascribed to be the primary alcohol attached to C-11 position. Finally, a crystal suitable

for X-ray analysis was grown from methanol and the structure was solved by the direct method. A computer-generated perspective drawing and bond lengths are shown in Fig. 1 and Table 3, respectively. As expected, two acetoxyl groups are β and the C-6 oxygen at C-6 is α .

Although the ¹H NMR and ¹³C NMR spectral data of **6** in CDCl₃ were essentially identical with those reported for a flavone, isolated from the same species collected in Pakistan [16] and ascribed structure 6', in the ¹H NMR spectrum in DMSO- d_6 , one D₂O exchangeable proton was observed in a low field region ($\delta_{\rm H}$ 12.89) together with five aromatic protons, as for the presumed 6'. The UV spectrum also showed some discrepancy in that on addition of AlCl₃ to the methanol solution, a significant bathochromic shift was observed in absorption band I (338 \rightarrow 372 nm),




Fig. 1. Computer-generated perspective drawing of compound 4.

[†] Could not be assigned due to the overlapping of many signals.

Table 3.	Bond	lengths	(Å) foi	r compou	nd 4	with	their	e.s.d	.'s
			in par	entheses					

F			
Atom	Atom	Distance	
O1	C3	1.48 (2)	
O 1	C16	1.41 (2)	
O2	C6	1.44 (2)	
O2	C12	1.36 (2)	
O3	C9	1.50(1)	
O4	C12	1.17(2)	
O5	C13	1.38 (2)	
O6	C16	1.15(2)	
O 7	C18	1.15 (2)	
C1	C2	1.49 (2)	
C1	C10	1.34(2)	
C2	C3	1.53 (2)	
C3	C4	1.49 (2)	
C4	C5	1.33 (2)	
C4	C15	1.50(2)	
C5	C6	1.49 (2)	
C6	C7	1.53 (2)	
C7	C8	1.51(2)	
C7	C11	1.33 (2)	
C8	C9	1.54(2)	
C9	C10	1.50(2)	
C10	C14	1.51 (2)	
C11	C12	1.49 (2)	
C11	C13	1.47(2)	
C18	C19	1.51 (2)	

while no shift was observed on the addition of sodium acetate, as was the case for 6'. This evidence strongly indicated that the free hydroxyl group must be located at the 5-position. Therefore, the structure of the flavone is most probably that shown as 6, which has been isolated from several sources as eupatilin 7-methyl ether (=5-hydroxy-6,7,3',4'-tetramethoxyflavone). Contrary to the melting point reported for santoflavone (150°), that of 6 (182°) was close to that reported for eupatilin 7-methyl ether (187–188° [17] and 188–189° [18]), and there was no optical rotation, as expected from the structure. With some revision of ¹³C NMR signal assignments, almost all HMBC correlations in the literature can be explained on the basis of structure 6.

EXPERIMENTAL

General. Mps: uncorr.; 1 H and 13 C NMR: 400 MHz and 100 MHz, respectively, with TMS as an int. standard; Prep. HPLC: ODS [Inertsil (GL Science, Tokyo): 20 mm × 250 mm with H₂O–MeOH at 6 ml min⁻¹ (A) or 6 mm × 250 mm with H₂O–MeOH at 1.6 ml min⁻¹ (B), detection: UV at 254 nm].

Plant material. Whole plants of Achillea santolina L. were collected from the West Desert, north of Egypt, in 1992. A voucher specimen was deposited in the Herbarium of the Faculty of Science, Minia University, El-Minia, Egypt.

Extraction and Isolation. The air-dried aerial parts of A. santolina (2.5 kg) were extracted with CHCl₃–MeOH (1:1, 3 l), \times 3 each for 48 hr. The combined extract was concd in vacuo and the residue was dissolved in 95% MeOH (1 l). The soln was washed with n-hexane (1 l) and the aq. MeOH layer was concd in vacuo. The residue was suspended in H₂O (1 l), and then the suspension was extracted with EtOAc (1 l) and n-BuOH (1 l) successively. The EtOAc layer was concd to give 55 g of residue.

The EtOAc Fr. was chromatographed over silica gel (200 g) with mixts of CHCl₃ and MeOH with increasing MeOH contents [CHCl₃ (2 l), CHCl₃-MeOH (199:1, 2 l), CHCl₃-MeOH (99:1, 2 l), CHCl₃-MeOH (24:1, 1.5 l), CHCl₃-MeOH (49:1, 1.5 l), CHCl₃-MeOH (47:3, 1.5 l), CHCl₃-MeOH (9:1, 1.5 l), CHCl₃-MeOH (7:1, 1.5 l), CHCl₃-MeOH (17:3, 1.5 l), CHCl₃-MeOH (7:3, 1.5 l) and CHCl₃-MeOH-H₂O (700:300:1, 1.5 l)] successively; 250 ml fr. were collected.

Frs 6–10 were combined and evapd in vacuo to give a residue (1.3 g), from which a mixt. of two crystalline materials was obtained by filtration. The mixt. was recrystallised from MeOH to give compound 6 as pale yellow crystals. While compound 1 was obtained in the mother liquid as colourless crystals, which were collected by filtration.

Frs 17–19 of the EtOAc fr. were combined and evapd in vacuo to give a residue (0.8 g), which was chromatographed over silica gel (50 g) with a solvent system [CHCl₃–n-hexane (9:1, 500 ml)], and was collected as one fr., and then with a gradient solvent system of CHCl₃–MeOH (199:1, 1 l \rightarrow 99:1, 1 l), frs of 8 g were collected. From frs 121–176, 400 mg of residue was obtained. On further sepn by HPLC (A) with a solvent system of 45% MeOH in H₂O, compound 3 (20.0 mg) was obtained ($R_t = 29 \text{ min}$).

Frs 25–57 of the same EtOAC fr. were combined and evapd *in vacuo* to give a residue (1.0 g), which was chromatographed over silica gel (50 g) with a solvent system [CHCl₃–n-hexane (9:1, 500 ml)], 500 ml, CHCl₃ and a gradient system CHCl₃–MeOH (199:1, 1 l)] and CHCl₃–MeOH (9:1, 1 l)], which was collected as four frs. Fr. no. 4 (350 mg) was rechromatographed over silica gel (50 g) with a gradient solvent system [CHCl₃–MeOH (199:1, 500 ml \rightarrow 99:1, 500 ml)], frs of 8 g were collected. From frs 44–70, 366 mg of residue was obtained, which was sepd by HPLC (A) using a solvent system of 40% MeOH in H₂O to give compound 2 (40 mg) (R_i = 28 min).

Frs 20–24 were combined and evapd in vacuo to give a residue (2.1 g), which was chromatographed over silica gel (50 g) with the same solvent system as for the previous fr., four frs were collected. Fr. nos. 3 and 4 were combined and evapd in vacuo to give a residue (1.1 g), which was rechromatographed over silica gel with a gradient solvent system [CHCl₃–MeOH (199:1, 1 1 \rightarrow 49:1, 1 l)], frs of 15 g were collected. From frs 34–50, compound 4 was obtained by HPLC (A) sepn using 50% MeOH in H₂O [$R_t = 29$

min]. While compound 8 (15 mg) was obtained as a yellow crystalline material from frs 57–76, which was sepd by filtration.

Frs 13-15 of the EtOAc fr. were combined and evapd *in vacuo* ti give a residue (1.5 g) which gave compound 7 (30 mg) as a yellow crystalline material.

Known compounds isolated. Leucodin (1), colourless crystals, mp 199–201°, $[\alpha]_D$ +19.1° (CHCl₃, c 0.62), ¹H and ¹³C NMR (CDCl₃): see Tables 1 and 2 [13]. Desacetylmatricarinin (2), colourless needles, mp 108° , $[\alpha]_D$ +20° (CHCl₃, c 0.17) [13]. Eupatolin (5,3′-dihydroxy-6,7,4′-trimethoxy flavone) (7), pale yellow crystals, mp 190–192° [17, 18] Cirsimartin (5,4′-dihydroxy-6,7-dimethoxy flavone) (8), pale yellow crystals, mp 262° [19].

5-Hydroxyleucodin (3). [α]_D +33.3° (CHCl₃, c 0.60), IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 3375, 2900, 1770, 1665, 1620, 1605, 1425, 1280, 1160, 985, 880; UV $\lambda_{\rm max}^{\rm MeOH}$ nm (log ϵ): 245 (3.97), 262sh (3.91); ¹H and ¹³C NMR (CDCl₃): Tables 1 and 2; HR-FAB-MS (negative centroid) m/z: 261.1136 [M-H]⁻ (C₁₅H₁₇O₄ requires 261.1127).

3,9-Diacetoxy, 13-hydroxy-1(10),4,7(11)-germacratrien-12,6-olide (4). Colourless crystals, mp 153–155°, $[\alpha]_D$ + 51.5° (CHCl₃, c 0.33), IR $v_{\rm max}^{\rm KBr}$ cm⁻¹: 3450, 2900, 1745, 1725, 1705, 1435, 1385, 1370, 1260, 1225, 1075, 1015, 990, 970; UV $\lambda_{\rm max}^{\rm MeOH}$ nm (log ε): 209 (4.23), 240sh (3.47); ¹H and ¹³C NMR (CDCl₃): see Tables 1 and 2; HR-FAB-MS (negative centroid) m/z: 363.1445 [M-H]⁻ (C₁₉H₂₃O₇ requires 363.1444).

Eupatilin 7-methyl ether (= santoflovone) (6). Pale yellow crystals, mp 184–186°, UV λ_{max}^{MeOH} nm (log ϵ): 214 (4.48), 242 (4.23), 275 (4.23), 338 (4.38), $\lambda_{max}^{MeOH + AcONa}$ nm (log ϵ): 214 (4.51), 242 (4.24), 276 (4.24), 338 (4.29), $\lambda_{\text{max}}^{\text{MeOH}+\text{AlCl}_3}$ nm (log ε): 216 (4.52), 262 (4.19), 288 (4.24), 372 (4.42); ¹H NMR (CDCl₃): δ 7.52 (1H, dd, J = 2.5 and 8.5 Hz, H-6'), 7.34 (1H, d, J = 2.5 Hz, H-2', 6.98 (1H, d, J = 8.5 Hz, H-5'), 6.60(1H, s, H-8), 6.54 (1H, s H-3). 3.94, 3.89, 3.86 and 3.74 (each 3H, each s, OMe \times 4); ¹H NMR (DMSO d_6): δ 12.89 (1H, s, ex. with D₂O, 5-OH), 7.70 (1H, dd, J = 2.5 and 8.5 Hz, H-6'), 7.58 (1H, d, J = 2.5 Hz, H-2'), 7.13 (1H, d, J = 8.5 Hz, H-5'), 7.01 (1H, s, H-8), 6.95 (1H, s, H-3), 3.94, 3.90, 3.87, 3.75 (each 3H, each s, OMe × 4); 13 C NMR (CDCl₃): δ 182.6 (C-4), 164.0 (C-2), 158.9 (C-7), 153.3, 153.1, 152.4, 149.4 (C-3'), 132.7 (C-6), 123.8 (C-1'), 120.1 (C-6'), 111.3 (C-5'), 108.9 (C-2'), 106.2 (C-10), 104.5 (C-3), 90.6 (C-8), 60.9 (OMe on C-6), 56.4, 56.2, 56.1 (OMe on C-7, 3' and 4'); 13 C NMR (DMSO- d_6): δ 182.5 (C-4), 163.9 (C-2), 158.9 (C-7), 152.9 (C-4'), 152.5 (C-5), 152.3 (C-9), 149.3 (C-3'), 132.2 (C-6), 123.1 (C-1'), 120.4 (C-6'), 111.9 (C-5'), 109.7 (C-2'), 105.4 (C-10), 103.9 (C-3), 91.9 (C-8), 60.3 (OMe on C-6), 56.8, 56.2, 56.0 (OMe on C-7, 3' and 4').

A single crystal X-ray analysis of 4. A crystal (0.2 mm × 0.3 mm × 0.4 mm) was grown by slow evapn of the MeOH. All data were obtained with a Rigaku AFC-5S automated four circle diffractometer with graphite-monochromated Mo-K α radiation. Crystal data: $C_{19}H_{24}O_7$, $M_r = 364.4$, orthorhombic, space

group $P2_12_12_1$, a = 10.313 (7) Å, b = 18.224 (4) Å, c = 9.083 (8) Å, V = 1842 (2) Å³, Z = 4, Dx = 1.314g cm⁻³, F(000) = 776, and μ (Mo $K\alpha$) = 0.935 cm⁻¹. The intensities were measured using the $\omega/2\theta$ scan mode up to 45°. Three standard reflections were monitored every 150 measurements. The data were corrected for the Lorentz and polarization factors. Absorption correction was applied, but decay correction was not applied. Of the 1436 independent reflections which were collected, 732 reflections with $I > 3.0\sigma(I)$] were used for the determination and refinement. The structure was solved by the direct method using a TEXSAN crystallographic software package [20]. All non-H atoms were found in a Fourier map. All H atoms were calculated at geometrical positions and not refined. The refinement of atomic parameters was carried out by the full matrix least squares refinement, using anisotropical temperature factors for all non-H atoms. The final refinement converged with R = 0.067 and $R_w = 0.069$ for 235 parameters. The minimum and maximum peaks in the final difference Fourier map were -0.19 and 0.26 eÅ⁻³. Atomic scattering factors were taken from the 'International Tables for X-ray Crystallography' [21]. The final atom coordinates, and a list of the temperature factors and final structure factors have been deposited at the Cambridge Crystallographic Data Centre, University Chemical Laboratory, Lensfield Road, Cambridge CB12 1EW, U.K.

Acknowledgements—One (B.A.A.A.B.) of the authors is grateful to the Egyptian Government for the financial support through the Channel System. The authors wish to thank Hiroshima University School of Medicine for the access to the superconductant NMR instrument at the Research Centre for Molecular Medicine.

REFERENCES

- Mishurova, S. S., Abbasov, R. M., Malinovskaya, T. A. and Mamadelieva, F. M., Rastitel'nye Resursy, 1985, 21, 69 (Chemical Abstract, 1986, 104, 85474w).
- Goldberg, A. S., de Salva, M. and Salvaltore, J., Journal of Pharmaceutical Sciences, 1969, 58, 938.
- Orkiszewska, A., Lobarzewski, R. and Jedrzejewska, M., Polish Patent, 1985, Pl 119 889 (International Patent Classification A61K35/78) (Chemical Abstract, 1986, 105, 139 611e).
- 4. Valant-Vetschera, K. H. and Wollenweber, E., Biochemical Systematics and Ecology, 1988, 16, 605.
- Ahmed, A. A., El-Sayed, N. H. and Mabry, T. J., Revista Latinoamericana de Quimica, 1989, 20, 5.
- Rücker, G., Manns, D. and Breuer, L., Archiv der Pharmazie, 1990, 323, 678.
- 7. Ulubelen, A., Öksuz, S. and Schuster, A., *Phytochemistry*, 1990, **29**, 3948.

- Linde, H. H. A. and Ragab, M. S., Helvetica Chimica Acta, 1967, 50, 7.
- Mallabaev, A., Abdullaev, N. D., Saitbaev, I. M., Yagdaev, M. R., and Sidyakin, G. P., Khimia Prirodnykh Soedinenii, 1984, 793.
- Stefanovic, M., Djermanovic, V., Gorunovic, M., Dermanovic, M., Macura, S. and Miloslavljevic, S., *Phytochemistry*, 1989, 28, 1765.
- 11. Rustaiyan, A., Sharif, Z., Taarodi, A. and Sadjadi, A. S., *Phytochemistry*, 1987, **26**, 2856.
- Yusopov, M. I., Mallabaev, A. and Sidyakin,
 G. P., Khimia Prirodnykh Soedinenii, 1976,
 396
- Mariano-Martinez, V., Munos-Zamora, A. and Joseph-Nathan, P., *Journal of Natural Products*, 1988, 51, 221.
- Gören, N., Öksüz, S. and Ulubelen, A., *Phyto-chemistry*, 1988, 27, 2347.

- Bohlmann, F., Borthakur, N., Jakupovic, J. and Pickard, J., *Phytochemistry*, 1982, 21, 1357.
- Ahmad, U. V., Khan, M. A., Baqai, F. T. and Tareen, R. B., *Phytochemistry*, 1995, 38, 1305.
- Ikram, M., Jehangir, S., Razaq, S. and Kawano, M., *Planta Medica*, 1979, 37, 189.
- Dobberstein, R. H., Tin-Wa, M., Fong, H. H. S., Crane, F. A. and Farnsworth, N. R., *Journal of Pharmaceutical Sciences*, 1977, 66, 600.
- Nair, A. G. R. and Sivakumar, R., Phytochemistry, 1992, 31, 671.
- TEXSAN, TEXRAY Structure Analysis Package, Molecular Structure Corporation, 3200 Research Forest Drive, The Woodlands, TX 77381, U.S.A., 1985.
- International Tables for X-ray Crystallography,
 Vol. IV. Kynoch Press, Birmingham, England,
 1964, Table 2.2A.